Application 212535
- Type
- NDA
- Sponsor
- AVADEL LEGACY
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | NOURESS | CYSTEINE HYDROCHLORIDE | SOLUTION;INTRAVENOUS | 500MG/10ML (50MG/ML) | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N212535-001 | NOURESS | CYSTEINE HYDROCHLORIDE | 500MG/10ML (50MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2019-12-13 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N212535-001 | 10478453 | 2039-01-15 | U-2752 | Drug product | 2020-07-28 |
| N212535-001 | 10583155 | 2039-01-15 | U-2752 | Drug product | 2020-07-28 |
| N212535-001 | 10653719 | 2039-01-15 | Drug product | 2020-07-28 | |
| N212535-001 | 10905713 | 2039-01-15 | Drug product | 2021-03-04 | |
| N212535-001 | 10905714 | 2039-01-15 | Drug product | 2021-03-04 | |
| N212535-001 | 10912795 | 2039-01-15 | Drug product | 2021-03-04 | |
| N212535-001 | 10918662 | 2039-01-15 | Drug product | 2021-03-04 | |
| N212535-001 | 10933089 | 2039-01-15 | Drug product | 2021-03-29 | |
| N212535-001 | 11510942 | 2039-01-15 | U-2752 | Drug product | 2023-03-24 |
| N212535-001 | 11642370 | 2039-01-15 | Drug product | 2024-05-17 | |
| N212535-001 | 11648262 | 2039-01-15 | Drug product | 2024-05-17 | |
| N212535-001 | 11679125 | 2039-01-15 | Drug product | 2024-05-17 | |
| N212535-001 | 11684636 | 2039-01-15 | Drug product | 2024-05-17 | |
| N212535-001 | 11826383 | 2039-01-15 | Drug product | 2024-05-17 | |
| N212535-001 | 12569514 | 2039-01-15 | Drug product | 2026-06-25 | |
| N212535-001 | 11510941 | 2039-03-02 | Drug product | 2023-03-24 | |
| N212535-001 | 10493051 | 2039-03-15 | Drug product | 2020-01-29 | |
| N212535-001 | 10543186 | 2039-03-15 | U-2722 | 2020-01-29 | |
| N212535-001 | 10702490 | 2039-03-15 | Drug product | 2020-08-04 | |
| N212535-001 | 11045438 | 2039-03-15 | Drug product | 2021-08-05 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N212535-001 | NOURESS | 500MG/10ML (50MG/ML) | SOLUTION / INTRAVENOUS | RLD | 2019-12-13 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10478453 | 2039-01-15 | U-2752 | Drug product | 2020-07-28 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10583155 | 2039-01-15 | U-2752 | Drug product | 2020-07-28 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10653719 | 2039-01-15 | Drug product | 2020-07-28 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10905713 | 2039-01-15 | Drug product | 2021-03-04 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10905714 | 2039-01-15 | Drug product | 2021-03-04 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10912795 | 2039-01-15 | Drug product | 2021-03-04 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10918662 | 2039-01-15 | Drug product | 2021-03-04 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10933089 | 2039-01-15 | Drug product | 2021-03-29 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11510942 | 2039-01-15 | U-2752 | Drug product | 2023-03-24 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11642370 | 2039-01-15 | Drug product | 2024-05-17 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11648262 | 2039-01-15 | Drug product | 2024-05-17 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11679125 | 2039-01-15 | Drug product | 2024-05-17 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11684636 | 2039-01-15 | Drug product | 2024-05-17 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11826383 | 2039-01-15 | Drug product | 2024-05-17 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 12569514 | 2039-01-15 | Drug product | 2026-06-25 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11510941 | 2039-03-02 | Drug product | 2023-03-24 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10493051 | 2039-03-15 | Drug product | 2020-01-29 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10543186 | 2039-03-15 | U-2722 | 2020-01-29 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 10702490 | 2039-03-15 | Drug product | 2020-08-04 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N212535-001 | 11045438 | 2039-03-15 | Drug product | 2021-08-05 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10478453 | 2039-01-15 | U-2752 | Drug product | 2020-07-28 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10583155 | 2039-01-15 | U-2752 | Drug product | 2020-07-28 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10653719 | 2039-01-15 | Drug product | 2020-07-28 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10905713 | 2039-01-15 | Drug product | 2021-03-04 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10905714 | 2039-01-15 | Drug product | 2021-03-04 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10912795 | 2039-01-15 | Drug product | 2021-03-04 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10918662 | 2039-01-15 | Drug product | 2021-03-04 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10933089 | 2039-01-15 | Drug product | 2021-03-29 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11510942 | 2039-01-15 | U-2752 | Drug product | 2023-03-24 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11642370 | 2039-01-15 | Drug product | 2024-05-17 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11648262 | 2039-01-15 | Drug product | 2024-05-17 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11679125 | 2039-01-15 | Drug product | 2024-05-17 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11684636 | 2039-01-15 | Drug product | 2024-05-17 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11826383 | 2039-01-15 | Drug product | 2024-05-17 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 12569514 | 2039-01-15 | Drug product | 2026-06-25 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11510941 | 2039-03-02 | Drug product | 2023-03-24 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10493051 | 2039-03-15 | Drug product | 2020-01-29 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10543186 | 2039-03-15 | U-2722 | 2020-01-29 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 10702490 | 2039-03-15 | Drug product | 2020-08-04 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N212535-001 | 11045438 | 2039-03-15 | Drug product | 2021-08-05 | c2088c7a36db… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CYSTEINE HYDROCHLORIDE | CYSTEINE HYDROCHLORIDE | Baxter Healthcare Corporation | cbf70fc3-14b3-4c17-8de8-acba1e12ac95 | 2022-04-29 | Warnings, Adverse reactions | 212535 NDA212535 0338-9645 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.